Suzhou, Dec. 29, 2020----Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the company won the Award of the Best Investor Relations Hong Kong-listed Company in the 2020 Annual Review of the Community of Futubull held by Futu recently, which was also the first time for the company to win this award.

Organized by Futu and based on a rigorous evaluation system, the winning companies were selected based on the work performance of each listed company’s investor relations on Futu platform for the year, with objective data in multiple dimensions such as information delivery and investor’s communications. Only 20 Hong Kong-listed companies were selected for the Award of the Best Investor Relations Hong Kong-listed Company, of which Kintor Pharmaceutical won the award together with other well-known companies such as Tencent and Xiaomi.

Kintor Pharmaceutical specializes in the development of potential “best-in-class”as well as the research, development and industrialization of “first-in-class” innovative drugs. Mainly focusing on the androgen receptor (AR)-related diseases, the Company researches and develops multi-channel product portfolio, covering high-morbidity cancers and other diseases which fails to satisfy clinic need, including prostatic cancer, breast cancer, liver cancer, COVID-19, alopecia, acne and other disease fields.

It’s worth noting that following the outbreak of COVID-19 pandemic, in February, the Company initialed a research and found its self-developed Proxalutamide could reduce the expression of ACE-2 and TMPRSS-2 proteins in normal lung cells which test ACE-2 positive. ACE-2 and TMPRSS-2 are two key types of proteins in the cells of the hosts contracted with COVID-19. The other day, Proxalutamide showed positive effect in Phase II clinical trials curing COVID-19 conducted in Brazil. Preliminary data shows that Proxalutamide can significantly reduce the hospitalization rate and severe cases of COVID-19 patients and accelerate the speed at which the virus in the body of patients turns from positive to negative, so as to slow down the process turning from mild case to severe case. Currently, the Company is proactively advancing the Phase III clinical trials internationally in China, America.

In the field of investor relation, in the past year, Kintor Pharmaceutical communicated with its investors and instilled its corporate values in time by virtue of official corporate account in the platforms of FUTU. The number of followers of its corporate account reached 46,000, and the page view of the contents released through the corporate account exceeded 1,000,000.

Through several performance teleconferences and online roadshows as well as the declaration and publication of several pieces of business progress information, Kintor Pharmaceutical demonstrated the Company’s vision, strategy and investment value to the investors, built an extensive and effective communication channel so as to offer the investors the latest information, and constantly output the development concepts and values of the Company so as to continuously strengthen the understanding, recognition and trust of the investors to the Company.

During this time, Kintor Pharmaceutical was honoured with the Award of Futu Annual Best Investor Relations Company, which highlighted the investors’ recognition on the business development, corporate governance and investor relations of the Company for the year 2020, affirmed the Company’s efforts and achievements in strengthening the communication with the capital market, and once again reflected the brand influence and reputation of the Company in the capital market. Looking forward, Kintor Pharmaceutical will keep delving into the industry, maintain a steady operation and expand the business development to give full play to its own advantages and reward the investors for their trust of the Company.